CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria:

* Life expectancy ≥ 3 months
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1
* Adequate organ function and hematologic reserve based on laboratory parameters
* Have measurable disease defined by RECIST v1.1
* Willingness to provide recent archival tumor tissue sample or willingness to undergo biopsy
* Tumor indication specific inclusion criteria:
* Is progressing from, intolerant to, or ineligible for (due to unavailability or contraindication) local standard of care therapies and have one of the following locally advanced or metastatic tumor types:

  * Head and Neck Squamous Cell Carcinoma (HNSCC)
  * Gastric/GEJ Cancer
  * Biliary Tract Cancer (BTC)
  * Esophageal Squamous Cell Carcinoma (ESCC)
  * Ovarian Cancer
  * Endometrial Carcinoma
  * Cervical Cancer
  * Non-Small Cell Lung Cancer (NSCLC)

Exclusion Criteria:

* Has malignancies other than disease under study within the past 3 years
* Has not adequately recovered from recent major surgery
* Has ongoing clinically significant toxicity related to prior therapy
* Has known sensitivity to any component of CR-002
* Has received prior treatment with an antibody-drug conjugate (ADC) with a topoisomerase I inhibitor payload.
* Has active central nervous system (CNS) metastases
* Has a medical or psychological condition that could interfere with study participation, increase risk, or affect interpretation of the study results
* NOTE: Other protocol defined Inclusion and Exclusion criteria may apply.